Figure 3.
p53 activator (PRIMA-1Met) and BRAF inhibitor (vemurafenib) radiosensitise V600EBRAF mutant melanoma in vivo. (A) Swiss nude mice (nu/nu) were injected by either MM043 and treated with CTR (DMSO), vemurafenib (45 mg/kg), PRIMA-1Met (50 mg/kg), or vemurafenib and PRIMA-1Met. One day later, the mice were irradiated on the right leg. Data are presented as means ± SEM (n = 9) compared to untreated tumors (B) Tumor volume of mice, non-irradiated (left panel), irradiated (right panel), untreated or treated with vemurafenib and/or PRIMA-1Met in the period between D0 and D36. ** p < 0.01, *** p < 0.001 (two-way ANOVA) compared to non-irradiated.